The chromosomal abnormalities associated with follicular lymphoma (FL) prognosis are not fully elucidated. Here, we evaluated the pattern of chromosomal abnormalities in FL, and clarified the correlations between the cytogenetic features and clinical outcome. Cytogenetic analysis was performed using standard methods of Giemsa-banding at diagnosis for 201 FL patients admitted to our hospitals between 2001 and 2013. The identified chromosomal abnormalities were: t(14;18)(q32;q21) (59Á2%), +X (17Á9%), del(6)(q)/-6 (16Á9%), +7 (14Á4%), abnormality of 1q12-21/1q (12Á9%), del (13)(q)/-13 (11Á9%), abnormality of 3q27 (10Á4%), abnormality of 10q22-24 (10Á0%), +12/dup(12)(q) (10Á0%), abnormality of 1p21-22/1p (9Á0%), +18 (9Á0%), del(17)(p)/-17 (5Á0%), and a complex karyotype (54Á7%). Patients with trisomy 21 had a significantly shorter progression-free survival (P = 0Á00171) and overall survival (OS) (P < 0Á001) than those without trisomy 21; additionally, patients with trisomy 21 in the rituximab-treated cohort also had a significantly shorter OS (P = 0Á000428). Multivariate analysis identified trisomy 21 as an independent risk factor in our cohorts with or without t(14;18) (P = 0Á015). In conclusion, the presence of trisomy 21 was an independent risk factor for in FL. Chromosomal analysis of FL patients at diagnosis can provide useful information about their expected survival.
Summary
The chromosomal abnormalities associated with follicular lymphoma (FL) prognosis are not fully elucidated. Here, we evaluated the pattern of chromosomal abnormalities in FL, and clarified the correlations between the cytogenetic features and clinical outcome. Cytogenetic analysis was performed using standard methods of Giemsa-banding at diagnosis for 201 FL patients admitted to our hospitals between 2001 and 2013. The identified chromosomal abnormalities were: t(14;18)(q32;q21) (59Á2%), +X (17Á9%), del(6)(q)/-6 (16Á9%), +7 (14Á4%), abnormality of 1q12-21/1q (12Á9%), del (13)(q)/-13 (11Á9%), abnormality of 3q27 (10Á4%), abnormality of 10q22-24 (10Á0%), +12/dup(12)(q) (10Á0%), abnormality of 1p21-22/1p (9Á0%), +18 (9Á0%), del(17)(p)/-17 (5Á0%), and a complex karyotype (54Á7%). Patients with trisomy 21 had a significantly shorter progression-free survival (P = 0Á00171) and overall survival (OS) (P < 0Á001) than those without trisomy 21; additionally, patients with trisomy 21 in the rituximab-treated cohort also had a significantly shorter OS (P = 0Á000428). Multivariate analysis identified trisomy 21 as an independent risk factor in our cohorts with or without t(14;18) (P = 0Á015). In conclusion, the presence of trisomy 21 was an independent risk factor for in FL. Chromosomal analysis of FL patients at diagnosis can provide useful information about their expected survival.
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Follicular lymphoma (FL) is defined as a nodular proliferation of B cells arising from the follicular centre of the lymph node (Lukes & Collins, 1974) , and is generally considered to be an indolent lymphoma. Over the last decade, the anti-CD20 monoclonal antibody, rituximab, has markedly improved the long-term outcome of FL, the current median overall survival (OS) of which is over 10 years (WagnerJohnston et al, 2015) . However, FL is still considered to be an incurable disease, and some FL patients experience multiple recurrences and a shorter survival period. Approximately 40% of FL patients will develop diffuse large B-cell lymphoma with a markedly worse prognosis (Kridel et al, 2012) . Many factors that are correlated with the clinical outcome of FL patients have been described, including age, sex, B symptoms, Ann Arbor stage, serum lactate dehydrogenase (LDH) level, serum albumin level, bone marrow involvement and the number of extranodal sites of disease. Some of these factors have been incorporated into prognostic indexes (Federico et al, 2000; Kondo et al, 2001; Solal-Celigny et al, 2004) .
The typical chromosomal abnormality in FL is the translocation t(14;18)(q32;q21), which is found in more than 75% of FL cases (Yunis et al, 1982 (Yunis et al, , 1984 Tilly et al, 1994; Tsukamoto et al, 2017) . Several other chromosomal abnormalities have also been found, including: extra copies of chromosomes 7, 12, 18, 21 or X; loss of chromosome 8, 13 or 15; research paper First published online 12 November 2018 doi: 10.1111/bjh.15664 del(6)(q); del(17)(p); and abnormalities of 1q and 1p (Schouten et al, 1990; Tilly et al, 1994; Johansson et al, 1995; Aamot et al, 2007) . Some of these chromosomal abnormalities are correlated with tumour histopathology, tumour evolution, and progression (Yunis et al, 1987; Tilly et al, 1994; Tsukamoto et al, 2017) . To improve the outcome and quality of life of FL patients, it is important to identify biomarkers that can identify high-risk patients who need intensive treatment at diagnosis. Recently, chromosomal and molecular abnormalities in FL patients have been detected by advanced molecular techniques, such as gene expression profiling, array comparative genomic hybridization (aCGH) and nextgeneration sequencing (Cheung et al, 2009; Morin et al, 2011; Bouska et al, 2014) . However, in clinical practice, biomarkers need to be easy and inexpensive to detect. For example, conventional karyotyping by Giemsa-banding (Gbanding) is routinely used for the diagnosis of non-Hodgkin lymphomas (NHL), regardless of histological subtype.
In this study, we evaluated the pattern of chromosomal abnormalities in FL using G-banding, and clarified the correlations between the cytogenetic features and clinical outcome.
Materials and methods

Patients
This study was approved by the Institutional Review Board of Gunma University. We enrolled 201 FL patients, who attended our hospital and/or affiliated hospitals between 2001 and 2013. The diagnosis of FL was made based on histological examination using the World Health Organization classification (Swerdlow et al, 2008) . Patients with histologically transformed FL at diagnosis or FL of the pathological subgroup Grade 3b were excluded from this study. Cytogenetic analysis by G-banding was performed using cells from the lymph node or other sites of disease. Ninety-nine (49Á3%) men and 102 (50Á7%) women with a median age of 59 years (range, 28-83 years) were included in the analysis. Clinical features, laboratory data, treatments, G-banding results, and the outcome of the patients were retrospectively analysed by reviewing clinical records. The median follow-up period was 48Á3 months. One hundred and sixty-five patients received rituximab-containing chemotherapy or rituximab monotherapy as an initial treatment. Throughout the entire study period, 175 patients (87Á1%) received rituximabcontaining chemotherapy or rituximab monotherapy.
Chromosomal analysis
Cytogenetic analysis by G-banding was performed by SRL Inc. (Tokyo, Japan) using cells from the lymph node or other sites of disease at diagnosis. The karyotype was described using the International System for Human Cytogenetic Nomenclature (Shaffer et al, 2013) . A complex karyotype was defined as the presence of three or more chromosomal aberrations.
Statistical analysis
Survival curves from the time of diagnosis were constructed using the Kaplan-Meier method, and significance was examined by the log-rank test. Progression-free survival (PFS) was defined as the time from diagnosis to the date of documented disease progression or of death from any cause. OS was defined as the time from diagnosis to death from any cause. Cox regression analysis was performed to examine the OS and PFS with different parameters as covariates. Factors from univariate analysis with cut-offs of P < 0Á1 were included in the multivariate analysis. The most appropriate model in multivariate analysis was selected based on the Akaike Information Criteria (AIC) (Akaike, 1998; Glatting et al, 2007) .
Sensitivity analysis was performed to assess the reliability of our results. In sensitivity analysis, we examined the several models. The factors for each analysis were included as follows; (i) clinical factors (age, clinical stage, B symptoms, bulky muss, LDH, soluble interleukin 2 receptor (sIL2R), FL International Prognostic Index (FLIPI), del(17)(p)/-17, 3q27 abnormalities, trisomy 7, trisomy 21, trisomy X, trisomy 12/ dup(12)(q) and complex karyotype), (ii) other clinical factors (B symptoms, bulky muss, sIL2R, FLIPI, del(17)(p)/-17, 3q27 abnormalities, trisomy 7, trisomy21, trisomy X, trisomy12/ dup(12)(q) and complex karyotype), which excluded the overlapping factors in FLIPI, such as age, clinical stage and LDH, (iii) factors for which no differences with or without trisomy 21 were observed, and (iv) factors which were significant in univariate analysis.
Correlations between trisomy 21 and clinical, biological and chromosomal abnormalities were evaluated by the Mann-Whitney U-test. A probability value of P < 0Á05 was considered to indicate statistical significance. All statistical analyses were performed with EZR (Saitama Medical Centre, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (Kanda, 2013) . levels were 11Á4%, 36Á3% and 33Á3%, respectively. One hundred and sixty-five patients (82Á0%) received rituximab-containing chemotherapy or rituximab monotherapy as an initial treatment (Table I) .
Results
Baseline characteristics of the study population
Chromosomal findings
Clonal chromosomal abnormalities were found in 176 patients (87Á6%). Table I shows the numerical or structural chromosomal abnormalities identified in more than 5% of the patients. t(14;18)(q32;q21) was the most common abnormality, which was observed in 119 patients (59Á2%). Other numerical or structural abnormalities that were identified in more than 5% of the patients were: +X (17Á9%); del(6)(q)/-6 (16Á9%); +7 (14Á4%); abnormality of 1q12-21/1q (12Á9%); del(13)(q)/-13 (11Á9%); abnormality of 3q27 (10Á4%); abnormality of 10q22-24 (10Á0%); +12/dup(12)(q) (10Á0%); abnormality of 1p21-22/1p (9Á0%); +18 (9Á0%); +21 (6Á4%); del (17)(p)/-17 (5Á0%); and a complex karyotype (54Á7%). In our cohort, there was no chromosomal translocation that was a variant form of t(14;18).
The influence of chromosomal abnormalities on survival
With a median follow-up period of 48Á3 months, the 3-year OS and PFS rates were 92Á8% (95% confidence interval [CI], 87Á9-95Á8) and 62Á0% (95%CI, 54Á4-68Á7), respectively (Fig 1) . To clarify the influence of chromosomal abnormalities on survival, Kaplan-Meier analysis was performed for chromosomal abnormalities found at a frequency of over 5% in our cohort. t(14;18)(q32;q21) showed no correlation with the clinical outcome. Patients with +21 (3-year PFS, 27Á8% vs. 64Á2%; P = 0Á00171) or with a complex karyotype (3-year PFS, 53Á1% vs. 72Á4%; P = 0Á00269) had a significantly shorter PFS than those without +21 or without complex karyotype (Table II ; Fig 2A,B) . The abnormalities of +21 (3-year OS, 45Á5% vs. 96Á1%; P < 0Á001), 3q27 (3-year OS, 65Á5% vs. 95Á6%; P = 0Á0002), del(17)(p)/-17 (3-year OS, 64Á3% vs. 94Á2%; P = 0Á0066), +7 (3-year OS, 84Á7% vs. 94Á1%; P = 0Á0369) and a complex karyotype (3-year OS, 87Á6% vs. 98Á8%; P = 0Á0301) were all associated with a shorter OS.
Prognostic impacts of chromosomal abnormalities
To clarify the prognostic impacts of chromosomal abnormalities, univariate and multivariate Cox regression analysis of PFS and OS were performed. Univariate analysis identified clinical stage (hazard ratio [HR], 1Á65; 95%CI, 1Á22-2Á23; P = 0Á0012), B symptoms (HR, 2Á21; 95%CI, 1Á18-4Á13; P = 0Á013), elevated LDH (HR, 1Á75; 95%CI, 1Á09-2Á83; P = 0Á021), elevated sIL2R (HR, 2Á47; 95%CI, 1Á13-5Á41; P = 0Á024), FLIPI score (HR, 1Á82; 95%CI, 1Á33-2Á49; All values are presented as n (%), unless otherwise stated. FLIPI, follicular lymphoma International Prognostic Index; LDH, lactate dehydrogenase; sIL2R, soluble interleukin 2 receptor. P = 0Á0002), trisomy 21 (HR, 3Á07; 95%CI, 1Á47-6Á46; P = 0Á0029), and a complex karyotype (HR, 2Á12; 95%CI, 1Á28-3Á50; P = 0Á0034) as risk factors for a shorter PFS, but only trisomy 21 (HR, 2Á75; 95%CI, 1Á17-6Á44; P = 0Á02), clinical stage (HR, 1Á61; 95%CI, 1Á14-2Á27; P = 0Á007), and a complex karyotype (HR, 1Á86; 95%CI, 1Á00-3Á45; P = 0Á048) were identified by multivariate analysis (Table III) . Concerning OS, univariate analysis selected clinical stage (HR, 2Á22; 95%CI, 1Á12-4Á40; P = 0Á022), B symptoms (HR, 6Á12; 95% CI, 2Á36-15Á83; P = 0Á00019), elevated LDH (HR, 3Á36; 95% CI, 1Á37-8Á24; P = 0Á008), FLIPI score (HR, 3Á36; 95%CI, 1Á60-5Á20; P = 0Á00044), del(17)(p)/-17 (HR, 4Á73; 95%CI, 1Á37-16Á29; P = 0Á014), 3q27 abnormalities (HR, 5Á15; 95% CI, 1Á96-13Á5; P = 0Á00089), trisomy 7 (HR, 2Á66; 95%CI, 1Á02-6Á94; P = 0Á045), trisomy 21 (HR, 10Á1; 95%CI, 3Á74-27Á22; P < 0Á0001), and a complex karyotype (HR, 2Á92; 95% CI, 1Á06-8Á03; P = 0Á039) as risk factors for a shorter OS (Table III) , but only B symptoms (HR, 4Á37; 95%CI, 1Á56-12Á28; P = 0Á0051) and trisomy 21 (HR, 6Á73; 95%CI, 2Á20-20Á58; P = 0Á00082) were selected by multivariate analysis. In sensitivity analysis, trisomy 21 was selected as a worse prognostic factor for PFS and OS (data not shown). We also evaluated OS in patients treated with only rituximab-containing chemotherapy or rituximab monotherapy. The +21 abnormality was also associated with a shorter OS in the rituximab treatment cohort (P = 0Á000428; Fig 3) . These data suggest that the presence of trisomy 21 was an independent risk factor for a lower PFS and OS in our cohort. The presence of trisomy 21 was associated with a higher age, 3q27 abnormality, trisomy 18, and a complex karyotype, while no significant differences were observed in the other factors, including clinical stage, histological grade, FLIPI score, B symptoms, presence of a bulky mass, and other chromosomal abnormalities, including t(14;18), nor between patients with or without trisomy 21 (Tables IV and V) .
Discussion
Chromosomal analysis is important for the diagnosis and prediction of prognosis for haematological malignancies. 
CI, confidence interval; OS, overall survival; PFS, progression-free survival. (17) (p)/-17, (d) +7, (e) +21, and (f) more than three chromosomal abnormalities (a complex karyotype). Solid lines indicate the patients without abnormalities, and dotted lines indicate the patients with abnormalities. The probabilities of PFS and OS were analysed using Kaplan-Meier analysis with a log-rank test. The P values were calculated. w, with; w/o, without.
Chromosomal Abnormalities in Follicular Lymphoma
Previous reports have found some chromosomal abnormalities to be associated with a poor prognosis in FL (Yunis et al, 1987; Tilly et al, 1994; Cheung et al, 2009; Bouska et al, 2014; Tsukamoto et al, 2017) . However, the prognostic value of chromosomal abnormalities in FL has not yet been fully elucidated in the era of rituximab. In this study, we analysed the chromosomal abnormalities in 201 FL patients using conventional karyotyping by G-banding and investigated the prognostic value of the chromosomal abnormalities in FL. Previous reports have shown that t(14;18)(q32;q21) is the most common abnormality in FL (Yunis et al, 1982) . We confirmed that t(14;18)(q32;q21) was the most common abnormality in our cohort; it was observed in 119 patients (59Á2%). Previous cytogenetic studies have also reported that numerical or structural chromosomal abnormalities, such as +X, +7, +12, +18, 1p21-22, 1q12-21, 3q27, 13q, 17p and 6q, are frequently observed (Tilly et al, 1994; Tsukamoto et al, 2017) . We also confirmed that these abnormalities were frequent in our cohort, and trisomy 21 was more frequently detected in our cohort than in the previous reports. Bouska et al (2014) showed various copy number abnormalities in FL using aCGH, including gains of 2, 5, 7, 6p, 8, 12, 17q, 18, 21 and X, and losses on 6q and 17p (Bouska et al, 2014) . Our G-banding findings were almost the same as those from aCGH, demonstrating that conventional karyotyping using G-banding is still useful and worthy of consideration for use in daily clinical practice.
Over the last decade, rituximab has improved the longterm outcome of FL, but it is still considered to be an incurable disease. To improve the outcome and quality of life of FL patients, it is important to identify biomarkers that can distinguish high-risk patients who need intensive treatment at diagnosis. However, the prognostic impact of chromosomal abnormalities in FL has not yet been fully elucidated. Previous studies have shown that the chromosomal abnormalities of 6q23-26, 17p, gain of X, loss of 1p36Á22-p36Á33, and loss of 6q13-15 are associated with a poor OS (Tilly et al, 1994; Cheung et al, 2009; Bouska et al, 2014) . Tsukamoto et al (2017) reported that the loss of 6q was associated with a shorter PFS in FL patients treated with 
CI, confidence interval; FLIPI, follicular lymphoma International Prognostic Index; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; RR, relative risk; sIL2R, soluble interleukin 2 receptor; ULN, upper limit of normal. rituximab-containing chemotherapy. However, we failed to detect any association between these cytogenetic abnormalities and a poor outcome in our cohort. We found that the presence of trisomy 21 was the only independent risk factor for a poor PFS and OS. Trisomy 21 has previously been reported to be frequent in t(14;18)-positive NHL (Yunis et al, 1987; Mohamed et al, 2001; Lestou et al, 2003; Bouska et al, 2014) ; however, its correlation with clinical parameters and outcome remains unclear. Several reports have mentioned an association between trisomy 21 and clinical outcome in FL. An early study suggested that the number of abnormalities and the presence of chromosomal alterations (6q-, +7, +X, +21) were associated with a poorer survival (Yunis et al, 1987) . Weisenburger et al (2000) showed an association between trisomy 21 and poor survival that was independent of t(14;18) in follicular large cell lymphoma. Aamot et al (2007) showed that both trisomy 21 and the presence of more than six secondary cytogenetic aberrations correlated with a shorter OS in FL. However, these results were obtained from patients in whom the treatments were unknown or who were not treated with rituximab (Yunis et al, 1987; Weisenburger et al, 2000; Aamot et al, 2007) . To our knowledge, only one report mentioned that patients with 6q-had a shorter OS in an R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like treatment group (Tsukamoto et al, 2017) . In our study, patients with trisomy 21 had a significantly shorter OS than those without trisomy 21 in the rituximab-treated group, and other chromosomal abnormalities, including 6q-, did not affect the clinical outcome. In our cohort, the presence of trisomy 21 was associated with a higher age and a complex karyotype when compared to patients without trisomy 21 (Tables IV and V) ; these differences might explain why trisomy 21 in FL was associated with an unfavourable clinical outcome in our cohort.
In conclusion, the presence of trisomy 21 might be an independent risk factor for a poorer PFS and OS in FL with and without t(14;18). Chromosomal analysis of FL patients at the time of diagnosis can provide useful information about their expected survival. The power of our study was restricted due to the limited number of patients with trisomy 21, and so larger studies analysing the survival of FL patients with trisomy 21 are needed to confirm these findings in the future. 
